Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
BMJ Publishing Group
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|